Mayo specialist for Cytopia

By Dylan Bushell-Embling
Wednesday, 30 July, 2008

Cytopia [ASX: CYT] has appointed a study chair for Phase I clinical trials of its new JAK2 enzyme inhibitor.

Dr Ayalew Tefferi is professor of medicine in haematology at the Mayo Clinic College of Medicine in the US.

JAK2 is a mutant enzyme which occurs in myelofibrosis patients, a disorder which causes bone marrow to be replaced by fibrous scar tissue. JAK2 can also cause other blood disorders, many of which can lead to conditions such as leukemia.

Cytopia expects to be ready to file an Investigational New Drug application for the treatment with the US FDA by the end of the year.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd